From The Industry Experts

31. What CROs Do Right Isn't Always Obvious To Research Sites 1/26/2026

    CROs are doing many things right. But it's when that right thing is understood — not just executed — that the impact becomes far greater than compliance alone.

32. How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials 1/26/2026

    VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.

33. Improving The eCOA Experience 1/25/2026

    Discover how template-driven builds and reuse can slash eCOA timelines by 50% while solving the licensing and translation hurdles that delay First Patient In.

34. 3 Clinical Research Attorneys Talk 2026 Trends 1/23/2026

    Three life sciences legal experts share what they see happening in the year ahead — and what should remain firmly in the past. 

35. Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders 1/23/2026

    Digital protocols could reduce manual effort and enable rapid and more consistent downstream study execution, reporting, and submission processes. TransCelereate BioPharma's Rob DiCicco and Novartis' Bill Illis explain.

36. Serbia: Europe's Emerging Clinical Trial Powerhouse 1/22/2026

    Discover why Serbia is becoming a top strategic choice for sponsors, including details of the country's strengths in key therapeutic areas, streamlined processes, and operational advantages.

37. The Intelligent Teammate: Agentic AI As A Catalyst For Clinical Innovation 1/22/2026

    Agentic AI cuts variability, speeds clinical workflows, and strengthens compliance. It boosts efficiency and supports teams as research demands grow. Explore the full article for insights.

38. Early Phase Clinical Trial Enrollment: How To Avoid Delays From The Start 1/22/2026

    By operationalizing the early-phase strategies discussed in this article, trial teams can ensure that foundational safety and efficacy data are captured without the delays that derail studies.

39. Changing The Clinical Feasibility Game With AI 1/22/2026

    AI is only as good as the data it’s built upon. Our customized AI platforms are constructed on a foundation of trustworthy, carefully curated data to produce detailed, expert-driven responses.

40. Navigating Late-Phase Clinical Trial Enrollment: Strategies To Stay On Schedule 1/22/2026

    Late-phase trial delays cause massive revenue loss. This piece outlines AI pre-screening, direct-to-patient scaling, and retention tactics to hit study goals on time and ensure market readiness.